Jeito Capital, an independent European private equity firm specialising in biopharma investments, has closed its second fund, Jeito II, at a record €1bn ($1.2bn billion), tripling the firm’s assets under management to €1.6bn.
The closing marks the largest raise ever by a fully independent European biopharma fund.
Jeito II will continue the firm’s proven approach of selectively backing 15–20 clinical-stage biopharma companies addressing severe diseases with high unmet medical needs. By increasing the average investment per company to around €150m, the fund aims to accelerate companies’ clinical development, market access, and commercial potential, creating long-term value for patients and investors alike.
Since its launch, Jeito has actively deployed capital across therapeutic areas including oncology, autoimmune diseases, neurology, cardio-metabolic conditions, obesity, and reproductive medicine. The fund leverages a multidisciplinary team of over 30 experts spanning drug development, regulatory affairs, intellectual property, commercial operations, and market access, providing portfolio companies with strategic guidance alongside capital.
Jeito’s patient-driven methodology has already delivered tangible results. Previous investments in EyeBio and Hi-Bio™ achieved successful exits through acquisitions by Merck & Co and Biogen, generating combined upfront payments of nearly $2.5bn with average holding periods of 24 months.
The fund attracted strong support from top-tier institutional and private investors across Europe, North America, and Asia, including sovereign and public funds, pharmaceutical companies, insurance groups, pension funds, family offices, and banks.
